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Abstract
Background: The purpose of this study was to determine the clinical parameters related to metamorphopsia
outcome in patients with resolved central serous chorioretinopathy (CSCR).
Methods: The charts of 36 eyes with resolved CSCR were retrospectively reviewed. We measured metamorphopsia
using M-CHARTS after resolution of serous retinal detachment. We analyzed the relationship between
metamorphopsia outcome and clinical parameters including age, visual acuity, chronicity of CSCR, symptom
duration and several spectral-domain optical coherence tomography findings using univariate and multivariate
forward logistic regression analyses.
Results: The M-CHARTS detected metamorphopsia in 19 eyes (52.8 %). In the univariate analysis, the eyes with
metamorphopsia were, relative to those without metamorphopsia, significantly associated with a greater proportion
of chronic-recurrent CSCR, initial and final irregularities of retinal pigment epithelium, longer symptom duration,
thinner final thickness of central fovea and outer nuclear layer, and final disruption of external limiting membrane
(ELM), photoreceptor inner and outer segment junction and cone outer segment tip line (P = 0.003, 0.037, 0.019,
0.003, 0.013, 0.015, <0.001, 0. 012 and 0.002, respectively). However, in the multivariate analysis, chronic-recurrent
CSCR (OR 22.5, P = 0.019) and final disrupted ELM (OR 82.6, P = 0.004) were the independent clinical parameters
related to poor metamorphopsia outcome.
Conclusions: Residual metamorphopsia was detected using M-CHARTS in about half of patients (52.8 %) with
resolved CSCR. Chronic-recurrent CSCR and final disrupted ELM were the independent clinical parameters related to
poor metamorphopsia outcome in patients with resolved CSCR.
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Background
Central serous chorioretinopathy (CSCR) is character-
ized by serous detachment of the neurosensory retina in
the macula which is associated with leakage at the level
of the retinal pigment epithelium (RPE). Generally,
CSCR is a benign and self-limiting disease with spontan-
eous resolution of serous retinal detachment (SRD) and
recovery of good vision. However, visual performance in
patients with CSCR can be compromised even after ret-
inal reattachment. The symptoms include loss of visual
acuity, metamorphopsia, micropsia, dyschromatopsia,
scotoma, and reduced contrast sensitivity. Many studies
have reported clinical features related to visual outcome
in patients with CSCR; they include symptom duration
[1], baseline visual acuity [1], outer nuclear layer
(ONL) thickness [2], as well as the integrities of the
photoreceptor inner and outer segment (IS/OS)
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junction [2–4] and cone outer segment tip (COST)
line [4].
Metamorphopsia is a major visual symptom in patients
with CSCR as residual metamorphopsia often leads to
poor visual quality even after recovery of good visual
acuity. Recently, several tools have been developed for
quantification of metamorphopsia severity including M-
CHARTS (Inami Co., Tokyo, Japan) [5], preferential hy-
peracuity perimeter (PHP) [6], and others. Nonetheless,
few studies have investigated the clinical parameters re-
lated to metamorphopsia severity in patients with CSCR
[7, 8]. Bae and Chae reported an M-CHARTS-quantified
correlation of high pigment epithelial detachment (PED)
incidence with metamorphopsia in patients with active
CSCR; however they did not analyze the clinical factors
related to poor metamorphopsia outcome after the reso-
lution of SRD [7]. Fujita et al., after half-dose verteporfin
photodynamic therapy (PDT) in patients with chronic
CSCR, found no significant correlation between metamor-
phopsia severity and the integrities of IS/OS junction and
COST line [8]. However, the clinical parameters related to
metamorphopsia outcome after resolution of SRD in pa-
tients with CSCR still have not been firmly established.
The purpose of this study was to determine the clinical
parameters related to metamorphopsia outcome after
resolution of SRD in patients with CSCR.
Methods
This is a retrospective cohort study. This study was ap-
proved by the Institutional Review Board of Kangnam
Sacred Heart Hospital and adhered to the tenets of the
Declaration of Helsinki. We retrospectively reviewed the
medical records of patients with resolved CSCR from
August 2014 to May 2015. Each patient had a docu-
mented episode of CSCR diagnosed by both fluorescein
angiography (FA) and spectral-domain optical coherence
tomography (SD OCT). We excluded the patients with
other retinal diseases including age-related macular de-
generation, polypoidal choroidal vasculopathy (PCV),
idiopathic choroidal neovascularization (CNV), epiret-
inal membrane (ERM), macular hole, vitreomacular trac-
tion, and other ocular diseases including proliferative
retinopathies, intraocular inflammation, glaucoma, and
amblyopia. Also excluded were patients with a history of
any systemic corticosteroid use or of ocular surgery ex-
cept uncomplicated cataract surgery.
The clinical data collected were age, sex, past ocular
history, symptom duration, chronicity of CSCR, and
treatment types. On the initial visit, all of the patients
underwent complete ophthalmic examinations including
measurement of best-corrected visual acuity (BCVA),
slit-lamp biomicroscopy, fundus examination, fundus
photography, FA, and SD OCT (Cirrus HD-OCT; Carl
Zeiss Meditec Inc, Dublin, CA). The final clinical data
including BCVA, fundus photography, SD-OCT and M-
CHARTS at 6–12 months after resolution of SRD were
obtained. Acute CSCR was defined as SRD self-resolving
within 6 months of symptom onset. Chronic-recurrent
CSCR was diagnosed in patients with visual disturbances
persisting for more than 6 months or recurrent episodes
of CSCR with multifocal or diffuse RPE decompensation
on FA. The patients were divided into two groups based
on the M-CHARTS-determined presence or absence of
metamorphopsia on the final visit.
The BCVA was converted to the logarithm of the min-
imal angle of resolution (logMAR). Indocyanine green
angiography (ICGA) was conducted to exclude PCV and
coexisting CNV. The SD-OCT scans were obtained in
the 5-line raster mode using a scan length of 6.0 mm
centered on the fovea. Based on each horizontal and ver-
tical SD OCT scan on the initial and final visit, the fol-
lowing foveal microstructures were evaluated: PED, RPE
irregularities, height of SRD, central foveal thickness
(CFT), thickness of ONL, and the integrities of the ex-
ternal limiting membrane (ELM), photoreceptor IS/OS
junction, and COST line. RPE irregularity was defined as
a condition including a small RPE bump, RPE hyper-
trophy or atrophy. The height of SRD as well as CFT
and ONL thickness were measured separately with the
OCT system’s built-in caliper. Specifically, the height of
SRD was measured as the distance between the outer
border of the sensory retina and the inner border of the
RPE at the fovea; the CFT was defined as the distance
between the internal limiting membrane (ILM) and the
outer border of the RPE at the fovea; the ONL thickness
was measured as the distance between the outer border
of the ILM and the ELM at the central fovea. Two separ-
ate values were obtained in horizontal and vertical scans,
respectively, which were averaged for the statistical ana-
lyses. The integrities of the ELM, IS/OS junction and
COST lines were graded as intact, a focal disruption
within 1000 μm from the foveal center and a broad dis-
ruption of more than 1000 μm. All of the SD OCT im-
ages were reviewed independently by two investigators
(HK and SHB) and a consensus was reached on each of
the results. If the patients showed persistent visual
symptoms or SRD over 3 months, or if they had a his-
tory of multiple recurrences, the treatments, including
laser photocoagulation and/or half-fluence PDT, were
considered at the discretion of the clinicians (HK and
SHB). In cases with obvious focal leakage located more
than 500 μm from the fovea on FA, the patient was
treated with laser photocoagulation. If laser photocoagu-
lation was not feasible, half-fluence PDT was applied to
the area of choroidal hyperpermeability shown in the
ICGA using a 6 mg/m2 dose of verteporfin followed by
delivery of a 689-nm laser with a reduced fluence of
25 J/cm2.
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In the patients with metamorphopsia, a straight line
appeared curved or irregular [5]. On M-CHARTS,
straight lines are replaced with dotted lines, and the dot
intervals (range: 0.2° - 2.0°) are changed from fine to
coarse. With increasing dot interval, the line distortion
decreases until the dotted line becomes straight. The vis-
ual angle that denoted the dot interval of the line seen
as straight was considered as the patient’s M-CHARTS
score. When a patient was tested with vertical dotted
lines, the result was defined as the vertical M-CHARTS
score. After the M-CHARTS were rotated 90°, the hori-
zontal M-CHARTS score also was measured according
to horizontal dotted lines. The presence of metamor-
phopsia subsequently was defined as either a vertical or
a horizontal M-CHARTS score equal to or greater
than 0.2°. The metamorphopsia severity was evaluated
by averaging the vertical and horizontal M-CHARTS
scores.
Statistical analyses were performed using SPSS (SPSS
version 17.0, SPSS, Inc., Chicago, IL). Comparisons be-
tween the two groups formed based on the presence or
absence of metamorphopsia were conducted using the
Mann–Whitney U test for the numerical variables and
the Chi-square test or Fisher’s exact test for the categor-
ical variables. The Spearman rank correlation test was
used to analyze the relationships between the numerical
variables and metamorphopsia severity. This analysis
was repeated excluding outliers as a sensitivity ana-
lysis. Outliers were defined as averaged M-CHARTS
scores smaller than 1.5 times of interquartile range or
greater than three times from the rest of the scores.
A multivariate forward logistic regression analysis was
performed to identify the independent parameters
associated with metamorphopsia outcome. The odds
ratio (OR) and 95 % confidence interval (CI) were es-
timated. A P value less than 0.05 was considered
statistically significant.
Results
We diagnosed 41 eyes of 38 patients with resolved CSCR
in the study period. However, five cases with resolved
CSCR were excluded because they were not followed-up
at least 6 months after the complete resolution of SRD.
Thus, 36 eyes of 33 patients with resolved CSCR were
included in this study. There were 28 men (84.8 %) and
5 women (15.2 %). The mean age was 50.8 ± 8.6 years
(range: 36–72 years). Acute CSCR was diagnosed in 14
eyes (38.9 %), and chronic-recurrent CSCR in 22
(61.1 %). The mean logMAR BCVA on the initial visit
was 0.2 ± 0.2 (range: 0.0–1.0). Thirteen eyes (36.1 %)
showed spontaneous resolution of SRD without any
treatment, whereas 23 (63.9 %) underwent treatments to
resolve the SRD: single half-fluence PDT in 13 eyes
(36.1 %), laser photocoagulation in five (13.9 %), and
both PDT and laser photocoagulation in five others
(13.9 %). After resolution of SRD, M-CHARTS detected
metamorphopsia in 19 eyes (52.8 %), whereas 17
(47.2 %) did not exhibit any abnormalities. The mean
vertical and horizontal M-CHARTS scores were 0.4 ± 0.5
and 0.3 ± 0.4, respectively, in the 19 study eyes with re-
sidual metamorphopsia on M-CHARTS.
The study eyes were divided into two groups
based on the M-CHARTS-detected presence or ab-
sence of residual metamorphopsia after resolution of
SRD. The comparisons of the demographic and
clinical parameters according to the presence or ab-
sence of metamorphopsia are summarized in Tables 1, 2
and 3. The ratio of chronic-recurrent CSCR and symptom
duration were significantly greater in eyes with metamor-
phopsia than in those without (P = 0.003 and 0.003, re-
spectively) (Table 1). On the initial visit, the incidence of
RPE irregularities was significantly greater in the eyes
with metamorphopsia than in those without (P = 0.037)
(Table 2). Among the final clinical parameters, the eyes
with metamorphopsia showed significantly thinner CFT
and ONL thickness, as well as higher incidences of RPE
irregularities and disrupted ELM, IS/OS junction and
COST line compared with those without metamorphopsia
(P = 0. 013, 0. 015, 0. 019, <0.001, 0.012 and 0.002, respect-
ively) (Table 3).
Metamorphopsia severity was significantly correlated
with symptom duration, final CFT and final ONL
thickness for the 36 total study eyes (ρ = 0.517, P = 0.001;
ρ = −0.383, P = 0.021; ρ = − 0.372, P = 0.025; respectively)
(Fig. 1), whereas no clinical parameters were significantly
correlated with metamorphopsia severity in the 19 eyes
with residual metamorphopsia. One outlier was identified
with a mean M-CHARTS score of 2.0. The case with ex-
treme outlier showed extensive disruption of ELM, IS/OS
junction and COST line finally with a prolonged symptom
duration of 16 months. After the removal of identified
outlier, the results were similar to those with outlier
as follows: metamorphopsia severity was significantly
correlated with symptom duration, final CFT and final
ONL thickness (ρ = 0.482, P = 0.003; ρ = −0.351, P = 0.039;
ρ = − 0.339, P = 0.047; respectively).
In the multivariate analysis, there were two inde-
pendent clinical parameters associated with poor
metamorphopsia outcome: chronic-recurrent CSCR
(OR 22.5, 95 % CI 1.7–306.3, P = 0.019) and disrupted
ELM on the final visit. The eyes with disrupted ELM
were associated with a higher risk of poor metamor-
phopsia outcome relative to those with intact ELM:
focal (OR 25.4, 95 % CI 1.6–394.2, P = 0.021) or
broad disrupted ELM (OR 82.6, 95 % CI 4.2–1630.0,
P = 0.004).
Two representative cases are shown in Figs. 2 and 3,
respectively.
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Discussion
Metamorphopsia is a common and significant symptom
of many retinal diseases. Several investigators have ana-
lyzed the prognostic factors affecting metamorphopsia
outcomes in several retinal diseases. They reported that
the CFT [9–11], ONL thickness [12], thickness of inner
nuclear layer (INL) [13, 14] and the integrity of IS/OS
junction [10] are related to metamorphopsia severity in
patients with ERM. Additionally, Bae and Chae reported
that higher incidence of PED is correlated with severe
metamorphopsia in patients with active CSCR [7]. How-
ever, they could not analyze the clinical factors related to
poor metamorphopsia outcome after the resolution of
SRD, because all patients did not show sustained meta-
morphopsia after the regression of subretinal fluid [7].
Still, the clinical parameters underlying metamorphopsia
remain controversial.
The present study investigated the clinical parameters
associated with metamorphopsia outcome in patients
with resolved CSCR. Metamorphopsia severity was
quantified using M-CHARTS, and clinical parameters
including the foveal microstructures were evaluated on
the basis of SD OCT images. Metamorphopsia was de-
tected in about half of the eyes (52.8 %) with resolved
CSCR using M-CHARTS, which result is compatible
with an incidence up to 67.7 % determined using the
Amsler chart [15]. Comparisons between the two groups
with and without metamorphopsia showed that metamor-
phopsia group was correlated with chronic-recurrent
CSCR and longer symptom duration as well as several
Table 1 Demographic parameters according to the M-CHARTS-detected metamorphopsia in patients with resolved central serous
chorioretinopathy
With metamorphopsia (n = 19) Without metamorphopsia (n = 17) P value
Age (years) 49.7 ± 8.7 52.1 ± 8.5 0.357
Sex, men : women (n) 14 : 5 16 : 1 0.182
Diagnosis, acute : chronic-recurrent (n) 3 : 16 11 : 6 0.003
Symptom duration (months) 10.5 ± 6.7 4.5 ± 4.0 0.003
Treatment
Spontaneous resolution (n, %) 6, 31.6 % 7, 41.2 % 0.549
Focal laser photocoagulation (n, %) 7, 36.8 % 3, 17.6 % 0.199
Photodynamic therapy (n, %) 10, 52.6 % 8, 47.1 % 0.738
Table 2 Initial clinical parameters according to the M-CHARTS-detected metamorphopsia in patients with resolved central serous
chorioretinopathy
With metamorphopsia (n = 19) Without metamorphopsia (n = 17) P value
BCVA (logMAR) 0.3 ± 0.3 0.2 ± 0.2 0.383
Height of subretinal fluid (μm) 190.6 ± 151.7 220.8 ± 153.0 0.447
Pigment epithelial detachment (n, %) 4, 21.1 % 6, 35.3 % 0.341
RPE irregularities (n, %) 11, 57.9 % 4, 23.5 % 0.037
External limiting membrane 0.25
Intact (n, %) 6, 31.6 % 9, 52.9 %
Focal disruption (n, %) 5, 26.3 % 5, 29.4 %
Broad disruption (n, %) 8, 42.1 % 3, 17.6 %
Photoreceptor IS/OS junction 0.342
Intact (n, %) 0, 0 % 0, 0 %
Focal disruption (n, %) 6, 31.6 % 8, 47.1 %
Broad disruption (n, %) 13, 68.4 % 9, 52.9 %
COST line 0.09
Intact (n, %) 0, 0 % 0, 0 %
Focal disruption (n, %) 3, 15.8 % 7, 41.2 %
Broad disruption (n, %) 16, 84.2 % 10, 58.8 %
BCVA best-corrected visual acuity, COST cone outer segment tip, IS/OS inner and outer segment, logMAR logarithm of the minimal angle of resolution, RPE retinal
pigment epithelium
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SD-OCT findings as follows: presence of initial and final
RPE irregularities, thinner final CFT and ONL thickness,
and disrupted ELM, IS/OS junction and COST line on the
final visit. Some of these findings are discordant with the
previous studies. Fujita et al. found no significant correl-
ation between metamorphopsia severity and the integrities
of the IS/OS junction and COST line after half-dose verte-
porfin PDT in chronic CSCR [8]. Okamoto et al. demon-
strated metamorphopsia to be unrelated to the degree of
ELM, IS/OS junction or COST disruption in patients with
ERM [13, 14]. Even so, the present multivariate analysis
showed the disappearance of structural parameters (ex-
cept final integrity of ELM) as prognostic factors. This re-
sult might have been due to structural changes, except
that final integrity of the ELM does not primarily affect
metamorphopsia outcome but merely results from the
clinical course of chronic-recurrent CSCR. Prolonged
SRD in patients with chronic-recurrent CSCR could lead
Table 3 Final clinical parameters according to the M-CHARTS-detected metamorphopsia in patients with resolved central serous
chorioretinopathy
With metamorphopsia (n = 19) Without metamorphopsia (n = 17) P value
BCVA (logMAR) 0.1 ± 0.3 0.1 ± 0.2 0.312
Central foveal thickness (μm) 159.4 ± 37.4 187.5 ± 32.6 0.013
Outer nuclear layer thickness (μm) 74.7 ± 25.0 94.5 ± 18.6 0.015
Pigment epithelial detachment (n, %) 2, 10.5 % 4, 23.5 % 0.391
RPE irregularities (n, %) 13, 68.4 % 5, 29.4 % 0.019
External limiting membrane <0.001
Intact (n, %) 2, 10.5 % 13, 76.5 %
Focal disruption (n, %) 6, 31.6 % 2, 11.8 %
Broad disruption (n, %) 11, 57.9 % 2, 11.8 %
Photoreceptor IS/OS junction 0.012
Intact (n, %) 0, 0 % 7, 41.2 %
Focal disruption (n, %) 6, 31.6 % 5, 29.4 %
Broad disruption (n, %) 13, 68.4 % 5, 29.4 %
COST line 0.002
Intact (n, %) 0, 0 % 0, 0 %
Focal disruption (n, %) 2, 10.5 % 10, 58.8 %
Broad disruption (n, %) 17, 89.5 % 7, 41.2 %
BCVA best-corrected visual acuity, COST cone outer segment tip; IS/OS inner and outer segment, logMAR logarithm of the minimal angle of resolution, RPE retinal
pigment epithelium
Fig. 1 Scattergrams showing correlations between metamorphopsia severity and clinical parameters including symptom duration (a), final
central foveal thickness (CFT) (b) and final thickness of outer nuclear layer (ONL) (c) for the 36 total study eyes with resolved central
serous chorioretinopathy. The metamorphopsia severity was evaluated by averaging the vertical and horizontal M-CHARTS scores. The
M-CHARTS scores showed significant correlation with symptom duration (ρ = 0.517, P = 0.001), final CFT (ρ = −0.383, P = 0. 021) and final
thickness of ONL (ρ = −0.372, P = 0.025)
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to permanent damage to overlying retinal structures,
resulting in retinal thinning and disruption of features of
the outer retinal layer such as the IS/OS junction, the
COST line and the RPE layer, even after resolution of
SRD. Ultimately, the key parameters responsible for meta-
morphopsia outcome, as determined in this study, are
chronic-recurrent CSCR and the final integrity of the
ELM.
Although several studies have suggested hypotheses
on the underlying mechanism of metamorphopsia in
several retinal diseases [12–14], in CSCR, it remains
unclear. Researchers have speculated that in patients
with ERM, the tractional force might damage the
inner retinal layer, and primarily the INL [12–14]. A
stretched INL, in turn, might cause damage to cellu-
lar components such as horizontal, bipolar, amacrine
and Müller cells, leading to disturbances in synaptic
transmission [12–14]. Whereas, Fujita et al. suggested
that in CSCR, metamorphopsia results from disrup-
tion to the regular alignment of the photoreceptor
layers followed by development of subretinal fluid [8],
but their investigation could not produce any corrob-
orating evidence.
The present results showed that final integrity of ELM
was the only independent structural parameter impacting
on metamorphopsia outcome in resolved CSCR. The
ELM represents the border between the outer part of the
ONL, composed of photoreceptor cell bodies, and the
inner photoreceptor segment. Thus, we speculated that
metamorphopsia in resolved CSCR can be attributed to
damage to the photoreceptor layer extending toward the
photoreceptor cell bodies, not to the outer parts of the
photoreceptor layer such as the IS/OS junction or COST
line. Furthermore, the ELM offers a junction for Müller
cells’ adherence to the base of the outer segment of the
photoreceptor layer. The inner half of the foveola is com-
posed of an inverted cone-shaped zone of Müller cells
designated as Müller cell cones [16], of which the trun-
cated apex is at the ELM. In addition, Müller cells play a
critical role in the control the homeostasis of retinal neu-
rons [17, 18], as well as, by neurotransmitter recycling, the
regulation of the synaptic activity in the inner retina [19].
Disruption of the ELM, therefore, might result in dysfunc-
tion of Müller cells, leading to disturbances in synaptic
transmission, and contributing thereby to the develop-
ment of metamorphopsia in resolved CSCR.
Fig. 2 Representative case of a 52-year-old man with acute central serous chorioretinopathy. Baseline fundus photography showed serous retinal
detachment (SRD) at the posterior pole (a). Baseline fluorescein angiography showed faint leakage at the level of retinal pigment epithelium
(b). Baseline cross-sectional image of spectral-domain optical coherence tomography (SD OCT) showed the SRD (c). The SRD was completely
regressed within 2 months of symptom onset without any treatment. At 8 months after complete resolution of SRD, the metamorphopsia was
not detected by M-CHARTS. The final SD OCT image showed intact external limiting membrane and photoreceptor inner and outer segment
junction (d). However, cone outer segment tip line was obscure
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This study has several limitations among which are
the retrospective design and the relatively small sample
size. Also, we obtained the final clinical data, including
the metamorphopsia measurements, at different time
periods after resolution of SRD, even though metamor-
phopsia and structural parameters could be improved
continuously according to the follow-up period. How-
ever, in previous studies, the numerical values of M-
CHARTS scores and the status of outer retinal layer
such as the IS/OS junction, the ELM, and the COST
line, were similar at 6–12 months after PDT in patients
with chronic CSCR [4, 8]. Thus, the present result might
not be significantly influenced by the measurements over
different time periods because we evaluated the severity
of metamorphopsia at 6–12 months after resolution of
SRD. In this study, the structural changes on the SD
OCT images were evaluated based only on a few cross-
sectional images centered on the fovea. That might be
suitable to evaluate the impact on the visual acuity
which reflects merely foveal function. However, investi-
gation of a broader retinal area might be necessary in
order to evaluate the relationships with metamorphop-
sia, not just visual acuity. Further studies with larger
sample sizes and serial follow-ups will be needed.
Conclusions
In conclusion, this study detected residual metamor-
phopsia using M-CHARTS in about half of patients
(52.8 %) with resolved CSCR. The independent clinical
parameters for poor metamorphopsia outcome were
chronic-recurrent CSCR and final disruption of ELM
after complete resolution of SRD in patients with CSCR.
Availability of data and materials
The dataset will not be shared, because there is an add-
itional ongoing study based on the dataset in part.
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Fig. 3 Representative case of a 52-year-old man with chronic central serous chorioretinopathy. Baseline fundus photography showed serous
retinal detachment (SRD) at the posterior pole (a). Baseline fluorescein angiography showed multiple mottled hyperfluorescent lesions at the
macula (b). Baseline cross-sectional image of spectral-domain optical coherence tomography (SD OCT) showed the SRD (c). The SRD was completely
regressed after half-fluence photodynamic therapy. At 6 months after complete resolution of SRD, the metamorphopsia was detected by M -CHARTS
with his vertical and horizontal M-CHARTS scores of 0.4 and 0.2, respectively. The final SD OCT image showed broad disruption of external limiting
membrane, photoreceptor inner and outer segment junction and cone outer segment tip line (d)
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